🇺🇸 BNT162b6 Bivalent (Original/OMI BA.4/BA.5) in United States

BNT162b6 Bivalent (Original/OMI BA.4/BA.5) (bnt162b6-bivalent-original-omi-ba-4-ba-5) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

BNT162b6 Bivalent (Original/OMI BA.4/BA.5) in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is BNT162b6 Bivalent (Original/OMI BA.4/BA.5) approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for BNT162b6 Bivalent (Original/OMI BA.4/BA.5) in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does BNT162b6 Bivalent (Original/OMI BA.4/BA.5) cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.